pembrolizumab,vibostolimab,favezelimab
merck
['mibc', 'pembro', 'key,note,57', 'nmibc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'blcsm']
breaking news from #gu23: keynote-057 cohort b shows that pembrolizumab proves promising for papillary, bcg-unresponsive, high-risk nmibc: #ascodailynews #blcsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.